Patents by Inventor Alexander J Kim

Alexander J Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND SYSTEMS FOR ROBOT-ASSISTED TOTAL KNEE ARTHROPLASTY
    Publication number: 20240065784
    Abstract: Robotic systems for orthopedic surgery are provided. The robotic systems may include at least first and second motors coupled to each other. An output shaft of one of the motors may be connectable to a surgical tool guide. An output shaft of another of the motors may be coupled to a portion of a ball and socket joint. A corresponding portion of the ball and socket joint may be coupled to a bone mount which may be attached to a bone to mount the first and second motors to bone for performing orthopedic surgical procedures.
    Type: Application
    Filed: August 25, 2023
    Publication date: February 29, 2024
    Inventors: Stuart L. Axelson, Alexander Raphe Massa, Anthony Joseph La Rosa, R. Michael Meneghini, Michael J. Taunton, Scott M. Sporer, James A. Browne, Raymond H. Kim
  • Tricyclic compounds as inhibitors of mutant IDH enzymes
    Patent number: 10508108
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)? or —N?; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis, Sara Esposite, Dawn M. Hoffman, Chunhui Huang, Solomon D. Kattar, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla, Zhicai Wu, Yang Yu, Craig R. Gibeau
  • Tricyclic compounds as inhibitors of mutant IDH enzymes
    Patent number: 10442819
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 15, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael Reutershan, Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig Gibeau, Tesfaye Biftu, Purakkattle Biju, Lei Chen, Joshua Close, Peter H. Fuller, Xianhai Huang, Min K. Park, Valdimir Simov, David J. Witter, Hongjun Zhang
  • Tricyclic compounds as inhibitors of mutant IDH enzymes
    Patent number: 10086000
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N?; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 2, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla, Chunhui Huang
  • NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
    Publication number: 20170369507
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Fischer Christian, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Michael J. Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Patrick Pengcheng Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig R. Gibeau
  • NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
    Publication number: 20170362220
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)? or —N?; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 21, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Michael J. Ellis, Sara Esposite, Dawn M. Hoffman, Chunhui Huang, Solomon D. Kattar, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Patrick Pengcheng Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla, Zhicai Wu, Yang Yu, Craig R. Gibeau
  • NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
    Publication number: 20170360800
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N?; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 21, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew Lloyd Childers, Francesc Xavier Fradera Llinas, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Nunzio Sciammetta, Patrick Pengcheng Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla
  • Cyclic amine substituted heterocyclic CETP inhibitors
    Patent number: 9353101
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 31, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John J. Acton, III, Feng Ye, Petr Vachal, Deyou Sha, James F. Dropinski, Lin Chu, Debra Ondeyka, Alexander J. Kim, Vincent J. Colandrea, Yi Zang, Fengqi Zhang, Guizhen Dong
  • CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS
    Publication number: 20150111866
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 23, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John J. Acton, III, Feng Ye, Petr Vachal, Deyou Sha, James F. Dropinski, Lin Chu, Debra Ondeyka, Alexander J. Kim, Vincent J. Colandrea, Yi Zang, Fengqi Zhang, Guizhen Dong
  • Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
    Patent number: 8796258
    Abstract: Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: August 5, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rajan Anand, James M. Apgar, Tesfaye Biftu, Ping Chen, Lin Chu, Vincent J. Colandrea, Guizhen Dong, James F. Dropinski, Danqing Feng, Jacqueline D. Hicks, Jinlong Jiang, Alexander J. Kim, Kenneth J. Leavitt, Bing Li, Xiaoxia Qian, Iyassu Sebhat, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS
    Publication number: 20130123237
    Abstract: Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: February 23, 2012
    Publication date: May 16, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Rajan Anand, James M. Apgar, Tesfaye Biftu, Ping Chen, Lin Chu, Vincent J. Colandrea, Guizhen Dong, James F. Dropinski, Danqing Feng, Jacqueline D. Hicks, Jinlong Jiang, Alexander J. Kim, Kenneth J. Leavitt, Bing Li, Xiaoxia Qian, Iyassu Sebhat, Lan Wei, Robert R. Wilkening, Zhicai Wu
  • Alkylquinoline and alkylquinazoline kinase modulators
    Patent number: 8071768
    Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: December 6, 2011
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Nand Baindur, Michael David Gaul, Kevin Douglas Kreutter, Christian Andrew Baumann, Alexander J. Kim, Guozhang Xu, Robert W. Tuman, Dana L. Johnson
  • Substituted 1,4-benzodiazepines and uses thereof
    Patent number: 7067512
    Abstract: The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: June 27, 2006
    Inventors: Tianbao Lu, Louis V Lafrance, III, Daniel J Parks, Karen L Milkiewicz, Raul R Calvo, Maxwell D Cummings, Alexander J Kim, Bruce L Grasberger, Theodore E Carver, Jr.
  • Substituted 1,4-benzodiazepines and uses thereof
    Publication number: 20030109518
    Abstract: The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 12, 2003
    Inventors: Tianbao Lu, Louis V. Lafrance, Daniel J. Parks, Karen L. Milkiewicz, Raul R. Calvo, Maxwell D. Cummings, Alexander J. Kim, Bruce L. Grasberger, Theodore E. Carver
  • Article of jewelry
    Patent number: D993062
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: July 25, 2023
    Assignee: Alexander Atelier, LTD.
    Inventor: Alexander J. Kim
  • Article of jewelry
    Patent number: D993063
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: July 25, 2023
    Assignee: Alexander Atelier, LTD.
    Inventor: Alexander J. Kim
  • Article of jewelry
    Patent number: D993064
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: July 25, 2023
    Assignee: Alexander Atelier, LTD.
    Inventor: Alexander J. Kim
  • Article of jewelry
    Patent number: D993065
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: July 25, 2023
    Assignee: Alexander Atelier, LTD.
    Inventor: Alexander J. Kim